OCEAN(a) CCTA

A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)”

Stage
inclusie
Medicine
Olpasiran
Population
Primaire preventie coronairlijden
Phase
III
First Patient In
1 May 2026
Last Patient In
12 December 2026
Last Patient Last Visit
19 May 2028

Inclusion period, 235 days remaining

Study Director

drs. J. Plomp

Cardioloog

Office Contact

S. Jansen

Studiemanager

The page has expired.